Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago, Illinois, from May 31 to June 4. In the context of bladder cancer, key studies included investigations into the efficacy and safety of combination therapies, including enfortumab vedotin paired with pembrolizumab. Other studies emphasized the importance of personalized treatment strategies, such as the use of FGFR inhibitors like erdafitinib for patients with specific genetic alterations, and the role of immune checkpoint inhibitors in both adjuvant and first-line settings. Additionally, new biomarkers and treatment approaches were discussed.
Scott T. Tagawa, MD
Professor of Medicine & Urology, Co-Leader, Cancer Therapeutics Program, Meyer Cancer Center, Weill Cornell Medicine, NewYork-Presbyterian Medical Center, New York, NY
“At ASCO 2024, I would say that the most relevant data for 2024 and 2025 going forward that most directly affects management — and, hopefully, patient outcome — were some updated data looking at enfortumab vedotin.”
Quick Clinical Takeaways
ASCO 2024: Key Insights Into Enhancing Treatment Efficacy and Managing Toxicity in Urothelial Carcinoma
Dr Tagawa reports on how data shared at ASCO 2024 on urothelial carcinoma included insights into enfortumab vedotin (EV) dosing, showing that higher initial doses improve response rates, but dose reductions and delays do not compromise efficacy and help manage toxicity. The EV-302 study provided long-term patient-reported outcomes, though its impact was less significant. Additionally, updated results affirmed that gemcitabine-cisplatin plus nivolumab is superior to gemcitabine-cisplatin alone for advanced urothelial carcinoma, particularly for patients with lymph node–only disease.
How Will My Patients Benefit?
ASCO 2024: Clinical Impact of New Data in Urothelial Cancer
Dr Tagawa discusses significant ASCO 2024 data on EV for advanced urothelial carcinoma, highlighting the importance of dose intensity and patient-reported outcomes. Dr Tagawa emphasizes that while EV, especially with pembrolizumab, may cause adverse events, dose reductions can improve patient tolerance without affecting treatment efficacy.
Polling Question
Summary
Highlights from ASCO 2024 on urothelial carcinoma include new data showing that higher initial doses of EV improve response rates, while dose reductions and delays effectively manage toxicity without compromising efficacy. The EV-302 study presented long-term patient-reported outcomes with minimal impact. Additionally, updated results confirmed the superiority of gemcitabine-cisplatin plus nivolumab over gemcitabine-cisplatin alone, particularly in patients with lymph node–only disease. Reflecting on these new data, Dr Scott Tagawa emphasized that adjusting EV doses can enhance patient tolerance while maintaining treatment effectiveness.
Resources:
